Dynamics of lipid metabolism in hypertensive patients who have had COVID-19 when the L-arginine + dihydroquercetin complex is included in the combined antihypertensive pharmacotherapy

Abstract

Purpose: To evaluate data on the dynamics of lipid metabolism in patients with arterial hypertension stage II who have had COVID-19, when the L-arginine complex + dihydroquercetin. Materials and methods: The article provides data on the dynamics of lipid metabolism in patients with arterial hypertension stage II who have had COVID-19, when the L-arginine complex (500 mg tablets 1 time per day) + dihydroquercetin (25 mg tablets 2 times) is included in combination antihypertensive therapy per day. Results: In patients who received combination antihypertensive therapy, which included statins (group 1), the target triglyceride value (<1.7 mmol/l) was not achieved. The target value for calculated low-density lipoprotein cholesterol (<3.7 mmol/L) was also not achieved. More significant changes in lipid metabolism were detected in patients (group 2) who took the L-arginine + dihydroquercetin complex as part of combined antihypertensive therapy, which included statins. Thus, in patients of group 2, total cholesterol and triglycerides decreased significantly (by 20-30%). There was also a significant decrease in this group of patients (by 30%) in the calculated indicator of low-density lipoprotein cholesterol and its target value was achieved (<3.7 mmol/l), namely 3.13±0.19 mmol/l. Summary: the inclusion of the L-arginine complex (tablets 500 mg 1 time per day) + dihydroquercetin (tablets 25 mg 2 times per day) in the combined AHT + statins in patients with stage II hypertension who have had COVID-19 is more effective than the combination AHT + statins affect OB, which is manifested by an improvement in its key indicators (TC, TG, LDL-C and HDL-C), as well as the calculated indicator of non-HDL-C.